Germany's BioNTech to buy CureVac to boost cancer research
legit.ng
منذ 22 ساعة
Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.
